These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 17068061)

  • 1. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis.
    Tynjälä P; Lindahl P; Honkanen V; Lahdenne P; Kotaniemi K
    Ann Rheum Dis; 2007 Apr; 66(4):548-50. PubMed ID: 17068061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis.
    Tynjälä P; Vähäsalo P; Honkanen V; Lahdenne P
    Ann Rheum Dis; 2009 Apr; 68(4):552-7. PubMed ID: 18467515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey.
    Foeldvari I; Nielsen S; Kümmerle-Deschner J; Espada G; Horneff G; Bica B; Olivieri AN; Wierk A; Saurenmann RK
    J Rheumatol; 2007 May; 34(5):1146-50. PubMed ID: 17343318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis.
    Saurenmann RK; Levin AV; Rose JB; Parker S; Rabinovitch T; Tyrrell PN; Feldman BM; Laxer RM; Schneider R; Silverman ED
    Rheumatology (Oxford); 2006 Aug; 45(8):982-9. PubMed ID: 16461435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients.
    Gerloni V; Pontikaki I; Gattinara M; Fantini F
    Ann Rheum Dis; 2008 Aug; 67(8):1145-52. PubMed ID: 17981916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Etanercept and uveitis in patients with juvenile idiopathic arthritis.
    Schmeling H; Horneff G
    Rheumatology (Oxford); 2005 Aug; 44(8):1008-11. PubMed ID: 15855187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry.
    Zannin ME; Birolo C; Gerloni VM; Miserocchi E; Pontikaki I; Paroli MP; Bracaglia C; Shardlow A; Parentin F; Cimaz R; Simonini G; Falcini F; Corona F; Viola S; De Marco R; Breda L; La Torre F; Vittadello F; Martini G; Zulian F
    J Rheumatol; 2013 Jan; 40(1):74-9. PubMed ID: 23118110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis--data from the dutch arthritis and biologicals in children register, 1999-2010.
    Otten MH; Prince FH; Twilt M; Ten Cate R; Armbrust W; Hoppenreijs EP; Koopman-Keemink Y; Wulffraat NM; Gorter SL; Dolman KM; Swart JF; van den Berg JM; van Rossum MA; van Suijlekom-Smit LW
    J Rheumatol; 2011 Oct; 38(10):2258-63. PubMed ID: 21844151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Indications and adverse events with the use of anti-TNFalpha agents in pediatric rheumatology: experience of a single center].
    de Oliveira SK; de Almeida RG; Fonseca AR; Rodrigues MC; Sztajnbok F; Diniz C
    Acta Reumatol Port; 2007; 32(2):139-50. PubMed ID: 17572652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Etanercept therapy in children with treatment-resistant uveitis.
    Reiff A; Takei S; Sadeghi S; Stout A; Shaham B; Bernstein B; Gallagher K; Stout T
    Arthritis Rheum; 2001 Jun; 44(6):1411-5. PubMed ID: 11407702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunomodulatory therapy with tumour necrosis factor α inhibitors in children with antinuclear antibody-associated chronic anterior uveitis: long-term results.
    Doycheva D; Zierhut M; Blumenstock G; Stuebiger N; Januschowski K; Voykov B; Deuter C
    Br J Ophthalmol; 2014 Apr; 98(4):523-8. PubMed ID: 24457365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Occurrence of inflammatory bowel disease in four patients with juvenile idiopathic arthritis receiving etanercept or infliximab.
    Tarkiainen M; Tynjälä P; Vähäsalo P; Lahdenne P
    Scand J Rheumatol; 2011 Mar; 40(2):150-2. PubMed ID: 20868307
    [No Abstract]   [Full Text] [Related]  

  • 13. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation.
    Galor A; Perez VL; Hammel JP; Lowder CY
    Ophthalmology; 2006 Dec; 113(12):2317-23. PubMed ID: 16996615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept.
    Braun J; Baraliakos X; Listing J; Sieper J
    Arthritis Rheum; 2005 Aug; 52(8):2447-51. PubMed ID: 16052578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.
    Gao X; Wendling D; Botteman MF; Carter JA; Rao S; Cifaldi M
    J Med Econ; 2012; 15(6):1054-63. PubMed ID: 22563743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The treatment of recurrent uveitis with TNF-alpha inhibitors].
    Falappone PC; Iannone F; Scioscia C; Grattagliano V; Covelli M; Lapadula G
    Reumatismo; 2004; 56(3):185-9. PubMed ID: 15470524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-TNF-alpha treatment: a possible promoter in endogenous uveitis? observational report on six patients: occurrence of uveitis following etanercept treatment.
    Kakkassery V; Mergler S; Pleyer U
    Curr Eye Res; 2010 Aug; 35(8):751-6. PubMed ID: 20673052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis.
    Smith JA; Thompson DJ; Whitcup SM; Suhler E; Clarke G; Smith S; Robinson M; Kim J; Barron KS
    Arthritis Rheum; 2005 Feb; 53(1):18-23. PubMed ID: 15696578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical remission in patients with systemic juvenile idiopathic arthritis treated with anti-tumor necrosis factor agents.
    Russo RA; Katsicas MM
    J Rheumatol; 2009 May; 36(5):1078-82. PubMed ID: 19435972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC Register.
    Otten MH; Prince FH; Anink J; Ten Cate R; Hoppenreijs EP; Armbrust W; Koopman-Keemink Y; van Pelt PA; Kamphuis S; Gorter SL; Dolman KM; Swart JF; van den Berg JM; Wulffraat NM; van Rossum MA; van Suijlekom-Smit LW
    Ann Rheum Dis; 2013 May; 72(5):721-7. PubMed ID: 22730374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.